NPM1 Mar 4, 2021 Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML Dec 6, 2020 ASH Study Highlights Race-Based Survival Disparities, Distinct Molecular Features in AML Patients Premium Mar 12, 2019 First Veterans Affairs MDx Lab Launches NGS-Based Cancer Panel; Others to Follow Premium Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
